INTERLEUKIN-1β levels are elevated in inflammatory bowel disease. In this study the mechanism by which interleukin-1β affects electrolyte transport in the rabbit distal colon, was investigated. Interleukin-1β caused a delayed increase in short-circuit current ($I_{sc}$) which was attributed to protein synthesis since the effect was inhibited by cycloheximide. The interleukin-1β induced increase in $I_{sc}$ was not affected by amiloride treatment but was completely inhibited by bumetanide or in chloride-free buffer and by indomethacin. Prostaglandin E$_2$ levels increased in tissue treated with interleukin-1β, but this increase was reversed by cycloheximide. These data suggest that interleukin-1β causes its effect via a yet to be identified second messenger, by increasing chloride secretion through a prostaglandin E$_2$ mediated mechanism.

**Key words:** Chloride secretion, Cytokines, Prostaglandin E$_2$

---

**Regulation of electrolyte transport with IL-1β in rabbit distal colon**

F. R. Homaidan, H. Desai, L. Zhao, G. Broutman and R. Burakoff

1Division of Gastroenterology and Nutrition, Winthrop-University Hospital and 2Department of Medicine, SUNY at Stony Brook, Mineola, NY 11501, USA

---

**Introduction**

IL-1 is a cytokine of around 17 kDa which is responsible for mediating a variety of processes in host defence, inflammation, and response to injury. It is produced by diverse cell types following infection or injury. On the basis of several overlapping activities and similar patterns of production, IL-1 may be grouped with tumour necrosis factor-α (TNFα), and IL-6 as factors mediating common effects. It is produced by a variety of cells such as fibroblasts and T and B lymphocytes and consists of two distinct but related molecules, IL-1α and IL-1β which are encoded by separate genes; in most human tissues IL-1β mRNA predominates over IL-1α mRNA. Both forms appear to function by binding to the same membrane-associated receptor. IL-1 appears to be a primary molecule in inflammatory reactions through its induction of other inflammatory metabolites, e.g. it induces production of prostaglandin E$_2$ (PGE$_2$) and phospholipase A$_2$ (PLA$_2$).

In the intestine, increased IL-1 production has been reported in the mucosa of patients with inflammatory bowel disease and in intestinal tissue of animal models of colitis, suggesting that IL-1 may be involved in the pathophysiology of inflammatory bowel disease. IL-1 has been shown to stimulate Cl$^{-}$ and HCO$_3^-$ secretion in the chicken intestine and inhibit Na$^+$ and Cl$^{-}$ absorption in rabbit ileum, however, the role and mechanism of action of IL-1 in affecting secretory function in the normal colon has not been fully elucidated.

More than one second messenger seems to be involved in mediating the effects of IL-1. Some of these mediators include nitric oxide (NO), CAMP and phospholipases C and A$_2$. In this study, the actions of IL-1β on electrolyte transport in normal rabbit distal colon and the second messenger(s) that might be involved in its mechanism of action are characterized. It was also determined whether TNFα has similar effects to IL-1 on ion transport in the rabbit colon since, although TNFα and IL-1 are biochemically distinct cytokines, they have many related and overlapping biological functions, and they play important and similar roles in many immune responses.

**Materials and Methods**

Human recombinant IL-1β, atropine, tetrodotoxin, indomethacin, amiloride, NG-1-nitro-$L$-arginine methyl ester (NAME), bumetanide, cycloheximide, actinomycin D and human recombinant TNFα were obtained from Sigma (St Louis, MO). For some experiments IL-1β was obtained as a gift from Drs P. Smith and J. Lee at Smith Kline and Beecham (Philadelphia, PA).

**Transport studies:** Male New Zealand albino rabbits weighing 2–3 kg were maintained on a standard rabbit chow diet with free access to water. The animals were killed by an overdose of pentobarbital sodium (i.v.). The distal colon was removed and epithelial sheets devoid of serosa and muscularis propria were prepared for transport studies. Colonic mucosa was mounted as a flat sheet between two Lucite modified Ussing chambers having an aperture of 1.13 cm$^2$, and oxygenated and maintained at 37°C. Short-circuit current ($I_{sc}$) which is equivalent to the electrical sum of all ion transport processes occurring simultaneously was determined. An automatic voltage clamp (W.P.I., Sarasota, FL), corrected for fluid
resistance between the potential difference sensing bridges, provided continuous short-circuiting of the tissue.

Unless specified, the bathing solution consisted of Krebs–HCO₃ (KBS) composed of (in mM): KCl 4.8, CaCl₂ 2.5, NaCl 118.1, NaH₂PO₄ 1.2, MgSO₄ 1.2, NaHCO₃ 25, glucose 11, pH 7.4 after gassing with 95% O₂/5% CO₂. Human recombinant IL-1β was used in this study. It has previously been shown that rabbit and human IL-1 cross-react with an antibody to human IL-1α and that rabbit and human IL-1 have approximately 65% homology. Amiloride and bumetanide were dissolved in 100% ethanol and indomethacin dissolved in 10 mM sodium carbonate. All reagents were added to the serosal bathing solution. Ion substitution studies were performed by either replacing Cl⁻ ions by gluconate ions or replacing HCO₃⁻ ions by HEPES solution.

Measurement of PGE₂ levels in tissue treated with IL-1β: Stripped distal colon mucosal sheets were washed with KBS, placed on ice and cut into small but equal pieces. For all assays, the tissue was transferred to polypropylene vials containing 5 ml of oxygenated KBS at 37°C in a slow shaking water bath. The tissue was continuously oxygenated during the experiment. Aliquots were transferred from the supernatant to Eppendorf tubes at specific times and centrifuged at 4°C, for 2 min at 7000 g in the Eppendorf centrifuge. Samples were kept at −70°C for later determination of PGE₂ levels using radioimmunoassay (RIA). Commercially available RIA kits for measurement of PGE₂ were used (Advanced Magnetics Inc., MA). The sample was precipitated with cold acetone, centrifuged and the precipitate discarded. Petroleum ether was then added to the supernatant and the aqueous phase separated and acidified to pH 3–4 and then extracted further with ethyl acetate. The sample was lyophilized and reconstituted in a known amount of assay buffer. In brief, the assay involved incubating the sample with the corresponding antiserum overnight at 4°C and then centrifuging for 15 min at 4°C at 1000 × g. The supernatant was then transferred to scintillation vials, scintillant was added and the vial counted in a liquid scintillation counter.

Statistical analyses: Statistical analyses were performed with Student's t-test for paired and unpaired data; half-maximal and maximal effects of IL-1β on transport were determined by the method of Woolf-Hanes by plotting the concentration/change in Iₛₑ vs. concentration. In these calculations, the half-maximal concentration and the maximal effect for each experiment were determined, and the results are presented as the means of these ± S.E. Unless specified all results are reported as mean ± S.E.

Results

Effects of IL-1β on Iₛₑ in rabbit distal colon: IL-1 (0.1 to 10 ng/ml) was added to the serosal bathing solution and Iₛₑ monitored for 60 min. IL-1β caused a significant, concentration dependent increase in Iₛₑ (Fig. 1A) with an EC₅₀ of 0.2 ng/ml. The peak increase in Iₛₑ was 24.1 ± 2.5 μA/cm² (basal Iₛₑ was 79.0 ± 13.5 μA/cm²) and was reached 40–50 min after the addition of IL-1β. This increase however was delayed and only observed 10–20 min after the addition of IL-1β (Fig. 1B).

Effects of IL-1β on Iₛₑ in the presence of indomethacin, atropine and TTX: To determine the mechanism by which IL-1β causes its effects on electrolyte transport, the colonic tissue was treated with either indomethacin (1 μM), a cyclooxygenase inhibitor which prevents the production of prostaglandins, atropine (1 μM), a cholinergic inhibitor, or TTX (1
Regulation of ion transport by IL-1β

β, a neuronal Na+ channel inhibitor which prevents neural input to the epithelial cells. IL-1β (1 ng/ml) was added to the serosal side of the colon in the Ussing chamber after pretreating the tissue with either of these inhibitors and the peak change in Icmc was measured. Indomethacin decreased the Icmc by 7.3 ± 2.1 μA/cm². It completely abolished the effects of IL-1β on Icmc (% ΔIcmc caused by IL-1β in the presence of indomethacin was −10.2 ± 13.2 μA/cm², Fig. 2) suggesting that IL-1β mediates most of its effects through the production of prostaglandins.

Atropine alone had no effect on Icmc and had no effect on IL-1-induced increases in Icmc. TTX, which alone caused a decrease in Icmc of 8.2 ± 0.7 μA/cm², inhibited the effect of IL-1β by 56 ± 17% (Fig. 2) indicating that while there is a large portion of the effect being mediated through enteric nerves, there is a possibility of a direct effect exerted on epithelial cells.

The nature of the ion involved in IL-1 effect: To determine the nature of the ion(s) whose transport is affected by IL-1 treatment, treatment of the tissue with amiloride, bumetanide or ion substitution studies were performed. Chloride ion was substituted for gluconate to determine if it is involved in the action of the cytokine. Amiloride, at 1 μM, an inhibitor of the apical Na+ channel, had no effect on the IL-1β induced increase in Icmc (14.3 ± 1.2 μA/cm² in control tissue vs. 14.3 ± 0.9 μA/cm² in tissue treated with amiloride, n = 3, p > 0.1, NS), suggesting that Na+ ion movement is not affected, while Cl− replacement completely reversed the increase in Icmc (Fig. 3). Bumetanide (10 μM), an inhibitor of the Na+/K+/2Cl− transporter present on the basolateral membranes of the crypt cells, had no effect on Icmc alone, also caused complete inhibition of the effect of IL-1β on Icmc (16 ± 1 μA/cm² in control tissues vs. 0 ± 2 μA/cm² in bumetanide treated tissue, n = 5, p < 0.005; and −9 ± 3 μA/cm² in chloride-free buffer, n = 5, p < 0.001). From these data we conclude that IL-1β causes a significant increase in anion secretion, mainly Cl−, which causes the increase in Icmc observed in the Ussing chamber.

The effect of IL-1β on the production of PGE2: Treatment of stripped tissue with IL-1β (1 ng/ml) caused a significant increase in the production of PGE2 (Fig. 4) compared with a time control (5 ± 1 ng/mg protein in control tissue vs. 12 ± 2 ng/mg protein in treated tissue, n = 6, p < 0.05). The time course for PGE2 production followed a similar course to the effect observed on Icmc in Fig. 1b. The levels of LTB4 were undetectable in control and in IL-1-treated tissues.

Effects of IL-1β in the presence of cycloheximide and actinomycin D: To test if protein synthesis is the reason for the delayed effect observed for the action of IL-1β, the tissue was treated with cycloheximide (100 μg/ml), a protein synthesis inhibitor, or with actinomycin D (10 μg/ml), a transcription inhibitor. As shown in Fig. 5, the effect of IL-1β on Icmc was significantly inhibited when the tissue was treated with cycloheximide on the serosal side for 15 min prior to the addition of the cytokine. The IL-1β-induced increase in Icmc in the presence of cycloheximide was 2.3 ± 1.2 μA/cm² vs. the effect of IL-1β alone, 16.3 ± 5.0 μA/cm² (n = 5, p < 0.001). Actinomycin D also caused an inhibition but this was not complete (Fig. 5). The IL-1β-induced increase in Icmc in the presence of actinomycin D was 4.8 ± 2.8 μA/cm² vs. the effect of IL-1β alone, 16.4 ± 3.1 μA/cm² (n = 5, p < 0.01). This is attributed to the short time of incubation (2 h) with the inhibitor since the tissue's conductance started to decrease after 3–4 h of...
mounting in the Ussing chambers. Neither cycloheximide nor actinomycin D had any effect on I_c when added alone. In all these experiments, Br-cAMP (100 μM) was added at the end of the experiment to test if either of the treatments (cycloheximide or actinomycin D) were toxic to the tissue. Br-cAMP caused a rapid increase in I_c of 29.0 ± 5.7 μA/cm² in control tissue compared with 29.0 ± 0.9 μA/cm² (p > 0.1, NS, n = 5) in tissue treated with cycloheximide and 21.8 ± 3.2 μA/cm² in tissue treated with actinomycin D (p > 0.1, NS; n = 5). These data suggest that indeed protein synthesis is involved in the effect of IL-1β on ion transport and would explain the delayed effect observed in I_c.

The effect of IL-1β on the production of PGE₂ in the presence of cycloheximide: Cycloheximide (100 μg/ml) significantly inhibited the increase in PGE₂ observed in tissue treated with IL-1β (Fig. 6). This suggests that IL-1β causes an increase in protein synthesis whose function is to increase the production of PGE₂ which in turn causes an increase in Cl⁻ secretion. Cycloheximide had no significant effect on PGE₂ production in control untreated tissue.

The effect of IL-1β in the presence of nitric oxide synthase (NOS) inhibitor: To test if NO is mediating the effects of IL-1 in the rabbit distal colon, NG-nitro-L-arginine methyl ester (NAME) at different concentrations (0.5–5 Mm) was added to the serosal surface of the tissue and the effect of IL-1β on I_c was tested. The increase in I_c caused by IL-1β was not affected by NAME added either at the same time with the IL-1β or 20 min before (I_c = 11.5 ± 1.3 μA/cm² in control tissue vs. 9.2 ± 1.8 μA/cm² in tissue pretreated with NAME (0.5 mM) for 20 min prior to IL-1 addition, vs. 8.2 ± 2.1 μA/cm² in tissue treated with NAME and IL-1β simultaneously, n = 5; p > 0.1, NS). Similar results were obtained with the different concentrations of NAME used (data not shown).

Discussion

Cytokines such as IL-1, possess a broad spectrum of biological activity. They are now being recognized as essential mediators of both normal and pathological immune responses such as temperature regulation, bone and cartilage remodelling, and regulation of extracellular matrix products. However, increased levels of these cytokines can lead to predominance of proinflammatory effects that characterize disease states such as sepsis and inflammatory bowel disease, and to the generation of inflammatory mediators such as leukotriene B₄ or PGE₂. In this study it is reported that IL-1β stimulates ion secretion through a mechanism which involves the production of PGE₂. The increase in PGE₂ production observed in this
study is consistent with the in vivo experiments reported by Cominelli et al. In the latter report, it was shown that in the isolated rabbit distal colon a 10 h infusion of IL-1 progressively increases production of PGE2, 6-keto PGF1α and thromboxane B2. In the present study it was found that the effect of IL-1 on Lc and on PGE2 production were not only concentration- and time-dependent but required protein synthesis. IL-1β caused an increase in Lc mainly by increasing Cl– secretion significantly with no effect on Na+ ion movement through the apical Na+ channel. In pancreatic islet cells, IL-1 was shown to activate the Na+/H+ exchanger and cause a rapid increase in cytosolic Na+ concentration. Since there is no evidence for the presence of the Na+/H+ exchanger in rabbit distal colon, the only possible explanation for the increased Lc is an increase in CI– secretion.

Most of the effects of IL-1β on Lc and PGE2 production were found to be through protein synthesis. Induction of protein synthesis in response to IL-1 treatment has been reported in a variety of cells. In these studies, alterations in phospholipid metabolism were observed. These were primarily due to increased PLA2 activity which occurred in response to IL-1 and which was attributed to induced synthesis of a phospholipase A2 activating protein. In human umbilical vein endothelial cells, IL-1 has recently been shown to induce cyclooxygenase-2 expression through a post-transcriptional regulation. In insulin-secreting cells IL-1 modulates the expression of specific proteins, not yet identified, but might represent heat shock protein, superoxide dismutase, or other proteins involved in the functional response of the islet to oxidative stress and free radical formation. Although the cell surface receptor for IL-1 has been cloned, it is still largely unknown how it transmits information to the inside of the cell after IL-1 binding. The intracellular signals induced by IL-1 appear to be complex because IL-1 seems to use multiple signal transduction pathways. In the beta cell, for example, nitric oxide (NO) has been implicated as the effector molecule responsible for some of the effects of IL-1 on cell function. NG-monomethyl-l-arginine (NMMA) and NAME, both of which are competitive inhibitors of nitric oxide synthase, prevent the inhibitory effects of IL-1β on glucose-stimulated insulin secretion by isolated islets. In our study, however, using a NOS inhibitor, we found no evidence for NO being a mediator for IL-1 action.

More than one second messenger seems to be involved in mediating the effects of IL-1. In different cell types, such as islets, pituitary, mesangial cells, chondrocytes and fibroblasts, different mediators have been described in association with cytokine action. Some of these mediators included Ca2+, inositol phosphates, CAMP, protein kinase A, PLC and PLA2 as well as alteration in gene transcription. In the intestine, the second messenger(s) involved in mediating the effect(s) of IL-1 is yet to be determined.

The human intestinal mucosa has been shown to be a rich source of IL-1 under normal conditions and that production of both forms, IL-1α and IL-1β, is dramatically increased during pathological conditions such as inflammation. IL-1 has been found to originate from mononuclear cells in the lamina propria but not from epithelial cells in normal or inflamed mucosa. Whether the receptor for IL-1 is present on epithelial cells, or not, is not yet known, although some evidence has emerged that IL-1β and IL-6 receptors have been identified on human epithelial cells suggesting that these cells can be regulated directly by proinflammatory cytokines.

In conclusion, this study demonstrates that IL-1 has profound effects on the secretory function of the normal distal colon. Since IL-1 is significantly increased in inflammatory bowel disease, an understanding of its mechanism of action on electrolyte transport in the colonic will lead to greater insights into the pathophysiology of inflammatory bowel disease and possibly new therapeutic modalities.

References
1. Dinarello CA. Biology of interleukin 1. FASEB J 1988; 2: 108-115.
2. Larrick JW, Kuinkel SL. The role of tumor necrosis factor and interleukin 1 in the inflammatory response. Pharmacol Rev 1988; 5: 129-159.
3. Saklatvala J, Guesdon F. Interleukin 1 and tumor necrosis factor signal transduction mechanisms: potential targets for pharmacological control of inflammation. J Rheumatol 1992; 19 (suppl): 65-69.
4. March CJ, Mosley J, Lumen A, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985, 315: 641-647.
5. Arii KI, Lee F, Miyajima A, Miyatake S, Arii N, Yokota T. Cytokines: coordination of immune and inflammatory responses. Annu Rev Biochem 1990; 59: 783-856.
6. Uegamisy M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease, enhanced production during active disease. Gut 1990; 31: 696-699.
7. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1β by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 1989; 30: 835-839.
8. Youngmen RS, Simon PI, West GA, et al. Localization of intestinal interleukin 1 activity and protein gene expression to lamina propria cells. Gastroenterology 1995; 104: 749-758.
9. Burdick R, Zhao L, Joseph I, Donovan V. The immunosuppressive agent FK506 prevents colitis and attenuates inflammatory mediator levels and myoelectric changes in a trinitrobenzenesulfonic acid model of colitis. Gastroenterology 1992; 102: A599.
10. Cominelli F, Naac CC, Clark RD, et al. Interleukin (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990; 86: 972-980.
11. Rachmilewitz D, Simon PL, Schwartz LF, Griswold DB, Pandacaro JD, Wasserman MA. Inflammatory mediators of experimental colitis in rats. Gastroenterology 1989; 97: 326-337.
12. Chang EB, Mosch MW, Mayer L. Interleukin 1 and 2 stimulate anion secretion in chicken intestine. Gastroenterology 1999; 98: 1548-1554.
13. Chiosis GC, Simon PL, Smith PL. Interleukin-1: effects on rabbit ileal mucosal ion transport in vivo. Gut J Pharmaco 1990; 14: 217-221.
14. Miled SB. Cyclic AMP and interleukin 1 signal transduction. Immunol Today 1990; 11: 390-391.
15. O'Neil LAJ, Bird TA, Saklatvala J. How does interleukin 1 activate cells? Interleukin 1 signal transduction. Immunol Today 1991; 11: 392-394.
16. Simon PL, Lee JC. Evidence for shared antigenic determinants on rabbit and human interleukin 1 (IL-1). J Immunol 1986; 137: 557-562.
17. Furutani Y, Nokote M, Yamayoshi M, et al. Cloning and characterization of the cDNA for human and rabbit interleukin-1 precursor. Nuclear Acid Res 1985; 13: 5869-5882.
18. Segel BI. Biochemical Calculations. New York: Wiley, 1976: 236.
19. Sandorff TJ, Streater EM, TNF and IL-1 in repsect: good cytokines gone bad. J Lab Clinc Med 1992; 179-180.
20. Cornelli F, Naac CC, Dinarello CA, Gentilini P, Zipser BD. Regulation of
eicosanoid production in rabbit colon by interleukin-1. Gastroenterology 1989; 97: 1400-1405.
21. Sandler S, Birkirk DL, Svensson C, Strandell R, Welsh M, Welsh N. Biochemical and molecular actions of interleukin-1 on pancreatic β-cells. Autoimmunity 1991; 10: 243-255.
22. Homalaski JS, Clark MS. Activation of phospholipase A2 in rheumatoid arthritis. Adv Exp Med Biol 1990; 279: 231-238.
23. Crowe RM, Staller TJ, Concroy RB, Storey CR. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem 1991; 266: 2657-2659.
24. Gilman SC, Chang J, Zeitler PB, Uh J, Mochan E. Interleukin-1 activates phospholipase A2 in human synovial cells. Arthritis Rheum 1988; 31: 126-130.
25. Godfrey RW, Johnson WJ, Newman T, Hoffstein ST. Interleukin-1 and tumor necrosis factor are not synergistic for human synovial fibroblast PLA2 activation and PGE2 production. Prostaglandins 1988; 35: 107-114.
26. Homalaski JS, Seiner MI, Simon PL, Clark MA. IL-1 increases phospholipase A2 activity, expression of phospholipase A2-activating protein, and release of linoleic acid from murine T helper cell line EL-4. J Immunol 1992; 148: 155-160.
27. Raimondi A, Giordano B, Wiestendorf J, Maling T, Hahn T. Induction of cyclooxygenase-2 by interleukin-1α: Evidence for post-transcriptional regulation. J Biol Chem 1994; 269: 11769-11775.
28. Helquist S, Hansen BS, Johannessen J, Andersen HE, Nielsen JH, Nenup J. Interleukin-1 up-regulates transcription of its receptor in human fibroblast cell line TIG-1. Evidence for endogenous PGE2 and cAMP. Eur J Immunol 1992; 22: 2516-2523.
29. Siita FJ, March CJ, Connon D, et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988; 243: 505-508.
30. Cochet L, Wang J, Streetland MA, Lancaster JR, McDaid ML. Interleukin 1β induces the formation of nitric oxide by β-cells purified from rodent islets of Langerhans. Evidence for the β-cell as a source of action of nitric oxide. J Clin Invest 1992; 90: 2384-2391.
31. Argiles JM, Lopez-Soriano J, Ortiz MA, Pou JM, Lopez-Soriano JP. Interleukin-1 and b-cell function: more than one second messenger. Endocr Rev 1992; 13: 515-524.
32. Chang J, Gilman SC, Lewis AJ. Interleukin-1 activates phospholipase A2 in rabbit chondrocytes: a possible signal for IL-1 activity. J Immunol 1986; 136: 1285-1287.
33. Gwosdow AR, O'Connor NA, Aboou-Samra AB. Interleukin-1 increases protein kinase A activity by a cAMP-independent mechanism in AT-20 cells. Am J Physiol 1994; 266: E79-E84.
34. Nakazato Y, Simonson MS, Herman WH, Konieczkowski M, Sedor JR. Interleukin-1 stimulates prostaglandin biosynthesis in serum-activated mesangial cells by induction of a non-pancreatic (type II) phospholipase A2. J Biol Chem 1991; 266: 14119-14127.
35. Heilschifer J, Schallweg G, Reiter VA, van den Bosch H. Cytokine-stimulated secretion of group II phospholipase A2 by rat mesangial cells. Contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells. J Clin Invest 1993; 92: 2516-2523.
36. Toh T, Akahoshi T, Kato K, Hayashi H, Maruouchi T, Onozaki K. Interleukin-1 up-regulates transcription of its own receptor in a human fibroblast cell line TIG-1: role of endogenous PGE2 and cAMP. Eur J Immunol 1992; 22: 1221-1227.
37. Panja A, Goldberg S, Mayer L. Expression and regulation of cytokine receptors on intestinal epithelial cells from normal controls and patients with IBD. Gastroenterology 1993; 97: 242-245.

Received 1 September 1994; accepted in revised form 19 October 1994